Selected Publication:
SHR
Neuro
Cancer
Cardio
Lipid
Metab
Microb
Marth, C; Windbichler, GH; Hausmaninger, H; Petru, E; Estermann, K; Pelzer, A; Mueller-Holzner, E.
Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study.
Int J Gynecol Cancer. 2006; 16(4): 1522-1528.
Doi: 10.1111/j.1525-1438.2006.00622.x
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
-
Petru Edgar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We have previously shown that interferon-gamma 1b (IFN-gamma) in combination with cyclophosphamide and cisplatin significantly prolongs progression-free survival in ovarian cancer. In this phase I/II study, we examined if administration of IFN-gamma is also safe in combination with the current standard treatment, paclitaxel and carboplatin. Thirty-four patients with newly diagnosed advanced epithelial ovarian cancer, FIGO stage III/IV, were treated for six to nine cycles with paclitaxel (175 mg/m(2)) and carboplatin (area under the curve [AUC] 5) every 3 weeks. IFN-gamma was administered in an escalating dose from 6 days/cycle with 0.025 mg sc up to 9 days/cycle with 0.1 mg sc. As expected, administration of IFN-gamma was associated with flu-like symptoms. Grade 3/4 neutropenia was observed in 74% (25 out of 34) of patients. Other side effects, in particular peripheral neuropathies, were within the previously observed ranges for the paclitaxel plus carboplatin combination. Overall response rate (complete or partial response) in patients who received either six or nine doses (0.1 mg) of IFN-gamma/cycle (n = 28) was 71%. IFN-gamma is safe in combination with carboplatin and paclitaxel for first-line treatment of patients with advanced ovarian cancer. This combination should be further evaluated as an immunotherapeutic treatment option for ovarian cancer.
- Find related publications in this database (using NLM MeSH Indexing)
-
Adenocarcinoma, Mucinous - drug therapy
-
Adult - drug therapy
-
Aged - drug therapy
-
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
-
Carboplatin - administration and dosage
-
Cystadenocarcinoma, Serous - drug therapy
-
Disease-Free Survival - drug therapy
-
Endometrial Neoplasms - drug therapy
-
Female - drug therapy
-
Humans - drug therapy
-
Interferon Type II - administration and dosage
-
Middle Aged - administration and dosage
-
Neoplasm Staging - administration and dosage
-
Ovarian Neoplasms - drug therapy
-
Paclitaxel - administration and dosage
-
Survival Rate - administration and dosage
-
Treatment Outcome - administration and dosage
- Find related publications in this database (Keywords)
-
carboplatin
-
interferon-gamma
-
ovarian cancer
-
paclitaxel